• Little is known about gynecological follow-up and cervical screening in CF.
• Only few studies have described contraceptive practices in cohorts of CF women (Plant 2008; Gatiss S 2009; Korzeniewska 2009 ).
• some papers have related oestrogen treatment with pulmonary status (Chotirmall 2012; Saint-Criq V 2014 ).
• there is no evidence that oral contraceptives might affect the severity of cystic fibrosis (Kernan NG 2013) .
• many CF patients with clinical conditions such as a previous pregnancy, diabetes mellitus, and pulmonary transplantation who need specific attention for contraceptive selection and gynaecological monitoring.
• Literature is scarce regarding gynaecological follow-up and cervical screening in this specific population.
Background Objectives
• To explore the contraceptive practices and gynaecological care for our patients • To compare the observed practices regarding recommendations in the general population and for specific clinical conditions.
Methods
• A self-report written questionnaire was proposed to all the 155 women attending the Lyon University adult CF centre in 2014.
• The gynaecological health care options and contraceptive choices were recorded.
• All patients attending the CF adult centre are included in a database (recorded clinical characteristics included the body mass index (BMI) and Forced Expiratory Volume (FEV1), as well as the presence of diabetes mellitus, hepatic cirrhosis, transplantation and a history of a previous pregnancy).
Results
• A total of 120 women answered the questionnaires, among whom two were postmenopausal (46 and 59 years of age), and 5 were pregnant • Contraceptive practice was recorded among the remaining 113
Results (1) • This is the first study to our knowledge to assess gynaecological follow-up and cervical screening among CF women.
• 74 % of the patients reported having a regular gynaecological follow-up, but only 53 % a yearly follow-up.
• A Pap smear test is an efficient, affordable and acceptable test for cervical cancer screening. In France, a Pap smear is recommended every 3 years for women aged 25 to 65, after 2 consecutive yearly normal Pap smear tests (HAS 2010). Only 42.5 % of our patients reported having had a Pap smear test in the previous 3 years, illustrating an insufficient gynaecological follow-up protocol.
• Among the transplanted patients, 58 % of the patients reported ever having had a Pap smear, and 6 of the 8 transplanted patients who had never had a Pap smear were older than 25 years of age. Considering the use of immunosuppressive treatment in these patients and the high rate of cervical dysplasia after transplantation (Malouf MA et al. 2004) , greater attention should be focused on cervical screening in this population.
• Only 64% of the premenopausal and non-pregnant women were using contraception. This proportion is close to those observed in other cohorts (Fair A et al. 2000; Tsang A et al. 2010; Plant BJ et al. 2008) , but lower than that of the French population (Bajos N et al. 2014) .
• This could reflect the fact that many CF patients are aware of their risk of infertility and thus do not consider themselves to be at risk of pregnancy. Women should be aware of their potential fertility and of the necessity to use efficient contraception. A high proportion of unplanned pregnancies has been described in a CF cohort indeed (Gatiss S et al. 2009 ).
•
No transplanted woman took the risk of unintended pregnancy. Considering the risks of pregnancy in this condition, efficient contraception is needed for all transplanted women with sexual activity (Gyi KM et al. 2006; Vos R et al. 2014 ).
• The proportion of condom users in our cohort was similar to that in the general population. Condom use is recommended for prevention of sexually transmitted infections (STIs) in young women especially in case of multiple partnership, as STIs can jeopardise future lung transplantation (Frayman KB and Sawyer SM, 2015) .
Discussion : contraception
• Two transplanted patients were using an IUD. Because of the possible risk of IUD failure under immunosuppressive treatments (Zerner J et al. 1981) , an IUD containing levonorgestrel should be preferred to a copper IUD in transplanted patients.
• Four percent of women had a tubal ligation. This contraceptive option must be discussed particularly in transplanted patients (Vos R et al. 2014 ).
• The proportion of women using oral contraception was high. Among the women using OCs, the proportion of women in our cohort using progestin-only OCs is higher than that among French women (26% (12/47) vs. 16%) (Bajos N et al. 2014 ). This could be explained by the specificities of contraception among the diabetic and transplanted patients. Combined OC can usually be used among with cystic fibrosis, except in case of specific contra-indication.
• Studies have suggested that oestradiol and oestriol have a deleterious effect on the disease (Chotirmall SH et al. 2012) , and some authors suggest a potential beneficial effect of hormonal contraception (Chotirmall SH et al. 2012) . In this studies, the type of OC used by the subjects was not known. Thus, these data are not sufficient to recommend hormonal contraception for its beneficial effect on the disease or to influence contraceptive selection among women with CF.
